• 제목/요약/키워드: JinKuiYaoLue

검색결과 4건 처리시간 0.022초

상한잡병론(傷寒雜病論) 계림고본(桂林古本) 처방(處方)에 대한 상한론(傷寒論)과 금궤요략(金匱要略)의 비교연구(比較硏究) (The comparative study on GuiLinGuBen "ShangHanZaBingLun"'s prescriptoins with "ShangHanZaBingLun" and "JinKuiYaoLue"'s)

  • 서영배;강한은
    • 대한한의학방제학회지
    • /
    • 제20권2호
    • /
    • pp.117-136
    • /
    • 2012
  • This thesis is the study on GuiLinGuBen "ShangHanZaBingLun"'s prescriptions which are totally 324, and unique 91 which are not written in current "ShangHanZaBingLun" and "JinKuiYaoLue", only in GuiLinGuBen "ShangHanZaBingLun". For modern clinacal effectiveness of GuiLinGuBen "ShangHanZaBingLun", this thesis clarifies the prescriptions' distinction between GuiLinGuBen, "ShangHanZaBingLun" and "JinKuiYaoLue". First it classifies prescriptions into 4 groups, which are only in GuiLinGuBen, in "ShangHanZaBingLun", in "JinKuiYaoLue", and in both "ShangHanZaBingLun" and "JinKuiYaoLue". Second it tabulates and describes in detail GuiLinGuBen's prescriptions about title, prescription composition, prescription volumetrin, decotion, and dosage. Third it catches distinctive characteristic of GuiLinGuBen's prescriptions by a comparative study which clarifies the differences of prescriptions between GuiLinGuBen, "ShangHanZaBingLun" and "JinKuiYaoLue". Current "ShangHanZaBingLun" and "JinKuiYaoLue"'s remedy focus on Shanghan and Jabbyong, so it has no choice but to have large remedy vaccum. The prescriptions only in GuiLinGuBen have same system with "ShangHanZaBingLun" and "JinKuiYaoLue"'s prescriptions, and contain unique Fever remover(淸熱劑) and Counterbalancer (補劑), so they could give more clinacal practice over "ShangHanZaBingLun" and "JinKuiYaoLue".

금궤요략의 상견복증(常見腹證)에 관한 연구(硏究) (A Study of Abdominal Syndrome in Jin Kui Yao Lue)

  • 홍문엽;박선동;박원환
    • 동국한의학연구소논문집
    • /
    • 제8권1호
    • /
    • pp.51-76
    • /
    • 1999
  • 금궤요략은 후한말기(後漢末期) 장기(張機)가 지은 임상의학(臨床醫學) 전문서적(專門書籍)으로써, 리(理) 법(法) 방(方) 약(藥)이 갖추어진 독창적(獨創的)인 변증론치체계(辨證論治體系)를 수립하고 있으며, 특히 복증(腹證)에 관한 내용을 중(重)히 다루고 있고, 방증변증(方證辨證)이 중심(中心)이 되어 복증(腹證)을 통한 변증(辨證)이 매우 발달되어 있어서 진단학(診斷學)의 발전(發展)에 크게 기여하였다. 이후 진단학(診斷學)의 발전(發展)은 진맥(診脈), 진설(診舌)을 위주로 했으며, 복진(腹診)의 운용(運用)에 대해서는 역사적으로 사회적인 특수한 배경으로 인하여 계속 발전되지 못하였다. 최근 한의학적(韓醫學的) 진단방법(診斷方法)과 치료방법(治療方法)이 매우 강조되어 활발한 연구가 계속 진행되면서 복증변증(腹證變證)에 관한 관심이 매우 집중되고 있기에, 복부진단(腹部診斷)에 관한 연구(硏究)의 한 방법(方法)으로써 금궤요략에 실려있는 상견복증(常見腹證)에 관련된 내용(內容)을 정리한 결과(結果) 약간의 지견(知見)을 얻었다.

  • PDF

"계림고본(桂林古本)" 상한논판본(傷寒論板本)의 처방구성에 대한 분석연구 (The statical analysis of GuiLinGuBon prescriptoin)

  • 서영배;강한은
    • 혜화의학회지
    • /
    • 제21권1호
    • /
    • pp.65-78
    • /
    • 2012
  • Found on the 19th century, GuiLinGuBon can have more several unique features than the other extinguish editions. GuiLinGuBon has been Receiving attention, because it contains both and 's contents, as well as it consistt of 16 books to the same as the preperce, and then it analyzed the chapter on Wending Disease(溫病) and Liuyin Disease(六淫病) in detail which is not written in current book, and gives several clues to solve many questions that caused the controversy. This thesis is the study the GuiLinGuBon on the overall composition and the prescriptions for the overall analysis to book configuration, herbs configuration, 8 method(八法) according to the prescribed frequency, SinNongBonChoGyong(神农本草经) according to the herbs of the SamPum(三品) classification and statistical processing GuiLinGuBon the specific features were analyzed.

Clinical Study of Hepatectomy Combined with Jianpi Huayu Therapy for Hepatocellular Carcinoma

  • Zhong, Chong;Li, Hui-Dong;Liu, Dong-Yang;Xu, Fa-Bin;Wu, Jian;Lin, Xue-Mei;Guo, Rong-Ping
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권14호
    • /
    • pp.5951-5957
    • /
    • 2014
  • Background: Traditional Chinese Medicine (TCM) possesses several advantages for treating patients with hepatocellular carcinoma (HCC). The theory of 'Jianpi Huayu Therapy' rooted from 'Jin Kui Yao Lue'is one of the most important therapies in this respect. This study was conducted to investigate the clinical effect and safety of hepatectomy combining with 'Jianpi Huayu Therapy' in the treatment of HCC. Materials and Methods: One hundred and twenty patients with HCC were randomized allocated into hepatectomy combined with 'Jianpi Huayu Therapy' group (treatment group, n=60) and hepatectomy alone group (control group, n=60). Disease- free survival (DFS) and overall survival (OS) were the primary end-points. Liver function at the end of one week after surgery, complications, average days of hospitalization as well as performance status (PS) at the end of one month post operation were also compared. Results: No significant differences existed between two groups on baseline analysis (p>0.05). No treatment related mortality occurred in either group. Post-operative complications were detected among 14 patients (23.3%) in the treatment group, and 12 (20.0%) in the control group (p=0.658). Alanine aminotransferase (ALT) at the end of one week after operation was lower in the treatment than control groups (p=0.042). No significant differences in other indexes of liver function were discovered between two groups. Average days of hospitalization reduced by 0.9 day in treatment group than in control (p=0.034). During follow-up, 104 patients (86.6%) developed recurrence. The rates of 1-, 3-, and 5-year DFS and median DFS for all patients were 77.4%, 26.3%, 9.0% and 25.6 months (range, 6.0~68.0), respectively (78.2%, 29.2%, 14.3% and 28.7 months for the 48 patients in the treatment group and 75.0%, 23.3%, 6.4%, and 22.6 months for the 56 patients in the control group (p=0.045)). 101 patients had died at the time of censor, with 1-, 3-, and 5-year overall survival rates and median survival for all patients of 97.5%, 76.4%, 40.5% and 51.2 months (range, 10.0~72.0), respectively (98.3%, 78.0%, 43.6% and 52.6 months, for treatment and 96.7%, 74.7%, 37.4%, and 49.8 months, for controls, respectively (p=0.048)). Conclusions: Hepatectomy combined with 'Jianpi Huayu therapy'was effective in the treatment of HCC, and reduced post-operative recurrence and metastasis and improved DFS and OS of HCC patients.